Posts

OneDayAdvisor Master Guide: Investing, AI, Technology & Health

By -
Image
OneDayAdvisor Master Guide & Site Index OneDayAdvisor is a research and decision platform covering money, investing, artificial intelligence, technology, healthcare and consumer decision-making. This master guide connects the site's major research areas, tools and practical guides in one place. Last updated:  October 2026  |  Purpose: Master pillar + site index Start here. OneDayAdvisor is designed around a simple idea: better decisions begin with better information. Instead of treating every topic as an isolated article, this site organizes research around the decision a reader is trying to make, the evidence needed to evaluate it, the risks involved and the tools available to help. On this page What Is OneDayAdvisor? Start Here: Choose Your Decision The OneDayAdvisor Knowledge Architecture Money & Investing ...
Post a Comment
Read more

Eli Lilly vs Novo Nordisk — The GLP‑1 Market Showdown (2026 Perspective)

By -
Image
By One Day Advisor Editorial Team · Last updated: October 2026  · Originally published November 2025 Quick Answer: Who is winning the GLP-1 market? Eli Lilly leads Novo Nordisk in GLP-1 medicines as of the October 26, 2026 close. Lilly's market value is about $1.14 trillion ($1,279.14 a share), roughly 6.6 times Novo's $172 billion, after Q2 revenue rose 48% to $22.97 billion. Lilly reports Q3 on October 29 and Novo on November 4; the FDA's CagriSema decision is due in Q4 2026. Disclosures Not investment or medical advice. This article is educational. Stock prices, clinical results and regulatory timelines change quickly; see the full disclaimer . This page contains no affiliate links. Company-reported trial results are sponsor-run; we label evidence quality using the CEBM hierarchy (1a/1b = randomized trials; 2b = lower-quality or early-phase trials; 3b = r...
Post a Comment
Read more